Back in May 2020, thanks to the Covid pandemic, the FDA had to press pause on domestic and foreign routine surveillance inspections, which piled up into a backlog of nearly 8,000 inspections.
Since then, however, the agency now makes clear in a new quality report that its number of surveillance inspections tripled in the last year, from 115 inspections in 2021 to 328 surveillance inspections in 2022. Some of that progress is thanks to agreements that the agency has with other countries, as it says 129 inspection classifications were due to Mutual Recognition Agreements with foreign regulators, and 49 were surveillance systems-based assessments using information from FDA requests.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters